^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Tecvayli (teclistamab-cqyv) (CD3 agonist, BCMA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
10/24/2022
Excerpt:
TECVAYLI is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Source:
Title:
Janssen Marks First Approval Worldwide for TECVAYLI® (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma
Published date:
08/24/2022
Excerpt:
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted conditional marketing authorisation (CMA) of TECVAYLI (teclistamab) as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM).
Source:
Published date:
10/31/2022
Excerpt:
Multiple Myeloma...Teclistamab-cqyv was added as an option after at least four prior therapies, including an anti-CD38 monoclonal antibody, a PI, and an IMiD.
Source:
Title:
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Published date:
06/01/2021
Excerpt:
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma.
Trial ID:
